Molnupiravir administered at human effect size-equivalent dose

molnupiravir dose  Conclusion Molnupiravir was safe and well tolerated; a dose of 800mg twice-daily for 5 days was recommended for Phase II evaluation  No dose adjustment of LAGEVRIO is required in patients with renal impairment

Patients were randomized to receive molnupiravir 800 mg PO twice daily for 5 days plus usual care or usual care alone The primary endpoint was How is Lagevrio® taken? Use this calendar to help keep track of your doses Note, if your first dose was in the evening on Day 1

68% of patients in the molnupiravir group had received at least three doses of mRNA vaccine or two doses of the S vaccine The peak plasma concentration of N-hydroxycytidine is reached hours after an oral dose of molnupiravir Doses do not need to be adjusted